Reported 28 days ago
In a recent discussion, Stacey Sears, portfolio manager at the Emerald Growth Fund, highlights the investment opportunities in small-cap biotech companies, emphasizing that they are driving significant advancements in healthcare, particularly in DNA and RNA editing as well as treatments for rare diseases. Sears points out that in 2023, two-thirds of clinical trials began with small biotech firms, accounting for over half of new drug approvals. She identifies Insmed and Wave Life Sciences as notable small-cap biotech stocks to watch as the sector rebounds from recent underperformance.
Source: YAHOO